GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    Paranasal sinusitis at the initiation of chemotherapy is a risk factor for invasive fungal disease in children and adolescents with cancer
    Springer Science and Business Media LLC ; 2021
    In:  Supportive Care in Cancer Vol. 29, No. 10 ( 2021-10), p. 5847-5852
    Details
    In: Supportive Care in Cancer, Springer Science and Business Media LLC, Vol. 29, No. 10 ( 2021-10), p. 5847-5852
    Type of Medium: Online Resource
    ISSN: 0941-4355 , 1433-7339
    URL: Article
    DOI: 10.1007/s00520-021-06143-7
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2021
    detail.hit.zdb_id: 1463166-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    Deletion analysis of the enolase gene ( enoA ) promoter from the filamentous fungus Aspergillus oryzae
    Springer Science and Business Media LLC ; 2001
    In:  Current Genetics Vol. 40, No. 4 ( 2001-12-1), p. 260-267
    Details
    In: Current Genetics, Springer Science and Business Media LLC, Vol. 40, No. 4 ( 2001-12-1), p. 260-267
    Type of Medium: Online Resource
    ISSN: 0172-8083 , 1432-0983
    URL: Article
    DOI: 10.1007/s00294-001-0258-7
    RVK:
    WA 15000
    Language: Unknown
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2001
    detail.hit.zdb_id: 1458984-9
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 3
    Online Resource
    Online Resource
    Clinical Outcomes after One-day or Two-day Intervals in Conditioning Regimens for allo-HCT
    Ovid Technologies (Wolters Kluwer Health) ; 2023
    In:  Journal of Pediatric Hematology/Oncology Vol. 45, No. 3 ( 2023-04), p. e378-e383
    Details
    In: Journal of Pediatric Hematology/Oncology, Ovid Technologies (Wolters Kluwer Health), Vol. 45, No. 3 ( 2023-04), p. e378-e383
    Abstract: One-day or two-day intervals are generally inserted into scheduled conditioning regimens for allogeneic hematopoietic cell transplantation, primarily due to various social circumstances, such as unexpected natural adversities, abrupt deterioration of patient health, and delays in graft source arrival. We compared the clinical outcomes of patients with interrupted conditioning with those with ordinarily scheduled conditioning. We analyzed 83 patients (children and adolescents) with oncologic disease who underwent myeloablative conditioning with total body irradiation. Overall and event-free survival were similar between the groups ( P =0.955, P =0.908, respectively). Non-relapse mortality and relapse rates were similar between the groups ( P =0.923, P =0.946, respectively). The engraftment rate was not affected by interruption ( P =1.000). In contrast, the incidence of chronic graft-versus-host disease (GVHD) was higher in the interrupted group compared with the scheduled group, although there was no statistical significance (42% vs. 19%, P =0.063). Conditioning interruption was identified to be an independent risk factor for chronic GVHD by multivariate analysis (odds ratio: 3.72; 95% CI: 1.04 to 13.3; P =0.043). In conclusion, apart from the incidence of chronic GVHD, clinical outcomes were not affected by one-day or two-day intervals during conditioning.
    Type of Medium: Online Resource
    ISSN: 1077-4114
    URL: Article
    DOI: 10.1097/MPH.0000000000002545
    Language: English
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date: 2023
    detail.hit.zdb_id: 2047125-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 4
    Online Resource
    Online Resource
    Pretransplant paranasal sinus disease is associated with a high incidence of transplant‐related mortality in hematopoietic stem cell transplantation for children and adolescents
    Wiley ; 2016
    In:  Pediatric Transplantation Vol. 20, No. 8 ( 2016-12), p. 1111-1116
    Details
    In: Pediatric Transplantation, Wiley, Vol. 20, No. 8 ( 2016-12), p. 1111-1116
    Abstract: To determine whether pretransplant PSD affects the clinical outcomes in HSCT , a retrospective cohort analysis of 73 pediatric and adolescent patients who underwent HSCT was performed. Pretransplant PSD was defined as the presence of a fluid level or mucosal swelling or total opacity on sinus X‐ray or CT examination performed before HSCT . Pretransplant PSD was observed in 21 (29%) patients. The probability of 2‐year OS after HSCT was 42% in patients with pretransplant PSD ( PSD group), and 64% in those without (non‐ PSD group) ( P =.012). The cumulative incidence of 2‐year TRM was 48% in the PSD group, and 17% in the non‐ PSD group ( P =.005). The cumulative incidences of pulmonary complications and respiratory failure at 2 years after HSCT were significantly higher in the PSD group (41% vs 15%, P =.022; 44% vs 14%, P =.009, respectively). PSD at the time of HSCT should be recognized as an additional potential risk factor for mortality. Further investigation is required to clarify the reasons for the present findings to improve the outcomes of patients with pretransplant PSD .
    Type of Medium: Online Resource
    ISSN: 1397-3142 , 1399-3046
    URL: Issue
    URL: Article
    DOI: 10.1111/petr.2016.20.issue-8
    DOI: 10.1111/petr.12793
    Language: English
    Publisher: Wiley
    Publication Date: 2016
    detail.hit.zdb_id: 2008614-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 5
    Online Resource
    Online Resource
    A randomized trial of cefozopran versus cefepime as empirical antibiotic treatment of febrile neutropenia in pediatric cancer patients
    Wiley ; 2014
    In:  Pediatric Blood & Cancer Vol. 61, No. 11 ( 2014-11), p. 1992-1995
    Details
    In: Pediatric Blood & Cancer, Wiley, Vol. 61, No. 11 ( 2014-11), p. 1992-1995
    Abstract: Febrile neutropenia (FN) is a common and serious complication of cancer chemotherapy associated with significant morbidity and mortality. Cefozopran (CZOP) is a potential candidate for empirical monotherapy in FN. However, studies on the use of CZOP as empirical treatment for pediatric patients with FN are quite limited. The purpose of this study was to compare the efficacy and safety of CZOP with cefepime (CFPM) empirical monotherapy in pediatric cancer patients with FN. Procedures A total of 64 patients with 224 episodes of FN were randomly assigned to receive antibiotic therapy with either CZOP (100 mg/kg/day) or CFPM (100 mg/kg/day). Of these episodes, 223 were considered eligible for the study. Success was defined as resolution of febrile episodes and clinical signs of infection within 120 hr following the start of antibiotic therapy. Results The success rate was not significantly different between the CZOP (64.0%) and CFPM (56.3%) groups ( P  = 0.275). Duration of fever, duration of antibiotic therapy, and the success rate in patients with blood stream infection did not differ between the two groups. There was no infection‐related mortality in the study period. Conclusion Both CZOP and CFPM as monotherapy appear to be effective and safe in pediatric patients. This study suggests that CZOP has satisfactory efficacy and is well tolerated as initial empirical therapy for pediatric cancer patients with FN. Pediatr Blood Cancer 2014;61:1992–1995. © 2014 Wiley Periodicals, Inc.
    Type of Medium: Online Resource
    ISSN: 1545-5009 , 1545-5017
    URL: Issue
    URL: Article
    DOI: 10.1002/pbc.v61.11
    DOI: 10.1002/pbc.25148
    Language: English
    Publisher: Wiley
    Publication Date: 2014
    detail.hit.zdb_id: 2130978-4
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 6
    Online Resource
    Online Resource
    A prospective randomized trial comparing piperacillin/tazobactam with meropenem as empirical antibiotic treatment of febrile neutropenic children and adolescents with hematologic and malignant disorders
    Wiley ; 2017
    In:  Pediatric Blood & Cancer Vol. 64, No. 6 ( 2017-06)
    Details
    In: Pediatric Blood & Cancer, Wiley, Vol. 64, No. 6 ( 2017-06)
    Abstract: This randomized prospective study was designed to assess whether piperacillin/tazobactam (PIPC/TAZ) is as effective as meropenem (MEPM) as a first‐line antibiotic treatment for febrile neutropenia (FN). Procedure FN episodes were randomly assigned to receive either PIPC/TAZ (337.5 mg/kg per day in three doses, 1‐hr DIV, maximum 13.5 g per day) or MEPM (120 mg/kg per day in three doses, 1‐hr DIV, maximum 3 g per day). Clinical responses were evaluated 120 hr after the DIV. Results A total of 434 febrile episodes in 105 patients (42 females and 63 males) with a median age of 8 years (range 0–25) were included in this trial. Blood cultures were positive in 47 out of the 434 episodes (10.8%). Regarding responses to the treatment, success rates between the PIPC/TAZ and MEPM groups were similar (62.4 vs. 65.9%, P = 0.484), even if patients were restricted to those with bacteremia (26.1 vs 37.5%, P = 0.534). Mortality rates did not significantly differ between the two groups (0.8 vs. 0%, P = 0.500). Conclusion Both PIPC/TAZ and MEPM appeared to be equally efficacious and safe. Carbapenems are now broadly used to treat FN; however, this may increase the prevalence of drug‐resistant bacteria. In this regard, the treatment using PIPC/TAZ for FN is more beneficial.
    Type of Medium: Online Resource
    ISSN: 1545-5009 , 1545-5017
    URL: Issue
    URL: Article
    DOI: 10.1002/pbc.v64.6
    DOI: 10.1002/pbc.26360
    Language: English
    Publisher: Wiley
    Publication Date: 2017
    detail.hit.zdb_id: 2130978-4
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 7
    Online Resource
    Online Resource
    Comparison of the Efficacy of Piperacillin/Tazobactam and Meropenem, with or without Intravenous Immunoglobulin, as Second-Line Therapy for Febrile Neutropenia: A Prospective, Randomized Study
    The Korean Society of Pediatric Hematology-Oncology ; 2021
    In:  Clinical Pediatric Hematology-Oncology Vol. 28, No. 2 ( 2021-10-31), p. 75-83
    Details
    In: Clinical Pediatric Hematology-Oncology, The Korean Society of Pediatric Hematology-Oncology, Vol. 28, No. 2 ( 2021-10-31), p. 75-83
    Type of Medium: Online Resource
    ISSN: 2233-5250 , 2233-4580
    URL: Article
    DOI: 10.15264/cpho.2021.28.2.75
    Language: English
    Publisher: The Korean Society of Pediatric Hematology-Oncology
    Publication Date: 2021
    detail.hit.zdb_id: 3011473-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 8
    Online Resource
    Online Resource
    Risk Factors of HHV6 Reactivation and Relationship Between Syndrome of Inappropriate Antidiuretic Hormone Secretion After Stem Cell Transplantation in Pediatric Patients
    American Society of Hematology ; 2011
    In:  Blood Vol. 118, No. 21 ( 2011-11-18), p. 4580-4580
    Details
    In: Blood, American Society of Hematology, Vol. 118, No. 21 ( 2011-11-18), p. 4580-4580
    Abstract: Abstract 4580 Many reports were seen about reactivation of human herpes virus 6 (HHV6) after stem cell transplantation (SCT) in adult patients, and this reactivation sometimes induce severe condition of patients. However, few reports were seen about pediatric patients. Therefore, we examined HHV 6 reactivation after stem cell transplantation in patients with children, retrospectively. The cases were 80 patients, 48 male, 32 female, and the median age was 6 years old (range 0–20 years old). Transplantations were 23 related bone marrow transplantations (BMT) or peripheral blood stem cell transplantations (PBSCT), 18 unrelated BMT, one related cord blood transplantation (CBT), 31 unrelated CBT, and seven autologous BMT or PBSCT. We analyzed HHV6 DNA samples of serum with these patients before SCT, 20 days and 40 days after SCT using PCR method. In addition, we analyzed relationship between HHV6 reactivation and syndrome of inappropriate antidiuretic hormone secretion (SIADH). In samples of 20 days after SCT, 35.0% of samples were positive for HHV6 DNA. On the other hand, 2.5% and 5.0% were positive before SCT and 40 days after SCT, respectively. From 24 out of 28 samples, over 10E3 of HHV6 DNA were detected in positive samples. Factors associated with HHV6 reactivation were CBT, unrelated donor, malignant diseases, use of total body irradiation as conditioning, cyclosporine and methyl prednisolone as GVHD prophylaxis, acute GVHD ( 〉 grade 2), chronic GVHD and use of steroid using univariate analysis. Moreover, CBT was an only risk factor of HHV6 reactivation using multivariate analysis. In 14 patients with SIADH, 78.6% of patients had HHV6 reactivation. On the other hand, 25.8% of patients had HHV6 reactivation in 66 patients without SIADH. This result was statistically significant (p 〈 0.001). From this analysis, we can understand HHV6 reactivation was seen in many patients with children. In addition, we thought about the possibility of SIADH is one symptom of the encephalopathy by the HHV6 reactivation. Disclosures: No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    URL: Article
    DOI: 10.1182/blood.V118.21.4580.4580
    RVK:
    XA 33000
    RVK:
    XA 10000
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2011
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 9
    Online Resource
    Online Resource
    Prophylactic Use of Voriconazole for Invasive Fungal Infection in Children and Adolescents with Acute Myeloid Leukemia
    American Society of Hematology ; 2015
    In:  Blood Vol. 126, No. 23 ( 2015-12-03), p. 2065-2065
    Details
    In: Blood, American Society of Hematology, Vol. 126, No. 23 ( 2015-12-03), p. 2065-2065
    Abstract: Background Invasive fungal infection (IFI) is a critical complication in the management of hematologic and malignant diseases. Patients with acute myeloid leukemia (AML) have been shown to be at high risk of IFI. Prophylactic therapy using antifungal agents is important for these patients because the timely and accurate diagnosis of IFI during the course of chemotherapy remains difficult. This study compared voriconazole (VRCZ) at a dose of 5 mg/kg/day versus 10 mg/kg/day for the prevention of IFI. Methods Between October 2005 and June 2011, 17 children and adolescents (9 boys and 8 girls, ages ranged from 0 to 20 years, with a median age of 7 years) undergoing chemotherapy for AML were prophylactically administered 5 mg/kg/day oral VRCZ starting at the beginning of chemotherapy. On the other hand, 22 patients (10 boys and 12 girls, ages ranged from 0 to 19 years, with a median age of 10 years) undergoing chemotherapy for AML were prophylactically administered 10 mg/kg/day oral VRCZ between July 2011 and December 2014. For prompt intervention against fungal infection, patients' blood samples were assayed for serum C-reactive protein by ELISA at least twice a week. When fever continued despite the administration of broad-spectrum antibiotics and/or a high level of C-reactive protein persisted, computed tomography (CT) of the chest and abdomen was performed and thoroughly inspected. In these patients, the detection of serum b-D glucan and Aspergillus galactomannan antigen was also carried out. IFI was defined and classified according to the standardized definitions from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Disease Mycosis study group (EORTC/MSG) consensus group. We compared the incidence of proven, probable or possible IFI during treatment between the 5 mg/kg/day and 10 mg/kg/day groups. The primary endpoint was freedom from IFI or death (fungal-free survival; FFS) at 180 days after the initiation of chemotherapy. Results Despite the prophylactic use of VRCZ, 8 patients developed IFI (proven 1, probable 3, possible 4). Of these 8 patients, 4 belonged to the 5 mg/kg/day group and 4 to the 10 mg/kg/day group. FFS rates at 180 days after the initiation of chemotherapy were similar between the 5 mg/kg/day and 10 mg/kg/day groups (70.9% vs. 73.8%, P =0.582). The trough concentration levels of VRCZ in the 10 mg/kg/day group ranged from 〈 0.09 to 2.17 mg/ml, with a median concentration of 0.27 mg/ml, and patients within the targeted trough concentration level (1 to 4 mg/ml) constituted only 18.8% of all evaluable patients, whereas the trough concentration levels of VRCZ of all patients in the 5 mg/kg/day group were below the limit of sensitivity ( 〈 0.09 mg/ml). In both groups, there were no cases forced to discontinue VRCZ due to adverse effects. No patients exhibited visual disturbances as an adverse effect of VRCZ. Conclusion Six-month FFS did not differ in children and adolescents with AML given prophylactic VRCZ at a dose of 5 mg/kg/day or 10 mg/kg/day. It is known to be more difficult to raise the concentration of VRCZ to the targeted concentration in children than in adults. Lower concentration levels of VRCZ might have served as a cause of the poor improvement in IFI prophylaxis despite an increased dosage. IFI prophylaxis using therapeutic drug monitoring of VRCZ might be able to improve FFS in patients with AML. Disclosures No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    URL: Article
    DOI: 10.1182/blood.V126.23.2065.2065
    RVK:
    XA 33000
    RVK:
    XA 10000
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2015
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 10
    Online Resource
    Online Resource
    Efficacy of liposomal amphotericin against febrile neutropenia in pediatric patients receiving prophylactic voriconazole
    Wiley ; 2021
    In:  Pediatrics International Vol. 63, No. 5 ( 2021-05), p. 550-555
    Details
    In: Pediatrics International, Wiley, Vol. 63, No. 5 ( 2021-05), p. 550-555
    Abstract: The risk factors for invasive fungal infection have gradually become evident for pediatric patients with hematological diseases. Here we analyze the efficacy of liposomal amphotericin (L‐AMB) for pediatric patients with febrile neutropenia using prophylactic voriconazole (VRCZ). Method We administered L‐AMB (2.5 mg/kg/day) in patients with febrile neutropenia who were receiving prophylactic VRCZ (10 mg/kg/day, orally) and were resistant to second‐line antibiotics therapy. Thirteen patients (5 males, 8 females) with 19 febrile neutropenia episodes were targeted in this analysis. The median age of the patients was 14 years (range, 1–19 years). Eighteen out of 19 episodes occurred in patients with acute myeloid leukemia, with the remaining episode occurring in a patient with acute unclassified leukemia. Results The median period from start of L‐AMB administration to resolution of fever was 4 days (1–27 days). In 15 out of 19 episodes, fever resolved within 5 days from commencement of L‐AMB administration. Using criteria proposed by T. J. Walsh et al., the success rate of L‐AMB for febrile neutropenia was 89.5% in this study. Conclusions Although the sample size of our study was small, the extremely high efficacy of L‐AMB warrants its administration in patients with febrile neutropenia who are receiving VRCZ.
    Type of Medium: Online Resource
    ISSN: 1328-8067 , 1442-200X
    URL: Issue
    URL: Article
    DOI: 10.1111/ped.v63.5
    DOI: 10.1111/ped.14450
    Language: English
    Publisher: Wiley
    Publication Date: 2021
    detail.hit.zdb_id: 2008621-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...